Investigation of Fenebrutinib Metabolism and Bioactivation Using MS<sup>3</sup> Methodology in Ion Trap LC/MS
Fenebrutinib is an orally available Bruton tyrosine kinase inhibitor. It is currently in multiple phase III clinical trials for the management of B-cell tumors and autoimmune disorders. Elementary in-silico studies were first performed to predict susceptible sites of metabolism and structural alerts...
Αποθηκεύτηκε σε:
| Κύριοι συγγραφείς: | , , , , |
|---|---|
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
MDPI AG
2023-05-01
|
| Σειρά: | Molecules |
| Θέματα: | |
| Διαθέσιμο Online: | https://www.mdpi.com/1420-3049/28/10/4225 |
| Ετικέτες: |
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|